Adagio Therapeutics downgraded by Stifel with a new price target
$ADGI
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded Adagio Therapeutics from Buy to Hold and set a new price target of $9.00 from $50.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $11.00 → $6.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/6/2022 | Overweight → Underweight | Morgan Stanley | |
| 12/22/2021 | $46.00 → $10.00 | Buy → Hold | Jefferies |
| 12/15/2021 | $49.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 12/15/2021 | Buy → Neutral | Guggenheim | |
| 12/15/2021 | $50.00 → $9.00 | Buy → Hold | Stifel |
| 11/29/2021 | $49.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/31/2021 | $33.00 | Equal-Weight | Morgan Stanley |
Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SARS-CoV-1 Antibodies target highly conserved epitopes under low immune pressure NVD200, a novel combination of two monoclonal antibodies, expected to advance into clinical trials in Q1 2023 WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD), formerly Adagio Therapeutics (NASDAQ:ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, announced today
Gainers Kiromic BioPharma, Inc. (NASDAQ:KRBP) shares rose 48.5% to $0.56 in pre-market trading. Kiromic Biopharma said the company has determined not to pursue, at this time, the contemplated public offering to which the registration statement relates. MSP Recovery, Inc. (NASDAQ:MSPR) shares rose 37.2% to $2.95 in pre-market trading after the company issued a business update. MSP Recovery recently posted Q2 loss of $0.09 per share. Signify Health, Inc. (NYSE:SGFY) rose 36.8% to $29.00 in pre-market trading after the Wall Street Journal reported that Amazon is among the potential bidders for the healthcare company, along with the previously reported CVS. Wag! Group Co. (NASDAQ:PET) ro
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen's 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 2:10 p.m. ET. A live webcast of the presentation will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, Inc., formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical company on a mission to prot
WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company's chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical. "On behalf of the company, I extend my gratitude and thanks for Laura's scientific passion and contributions that led to
WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to s
8-K - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
D - Invivyd, Inc. (0001832038) (Filer)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)
Morgan Stanley downgraded Adagio Therapeutics from Equal-Weight to Underweight and set a new price target of $6.00 from $11.00 previously
Morgan Stanley downgraded Adagio Therapeutics from Overweight to Underweight
Jefferies downgraded Adagio Therapeutics from Buy to Hold and set a new price target of $10.00 from $46.00 previously
Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022. "It has been a productive quarter starting with a corporate rebrand emphasizing our commitment to e
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan o
WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing f
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors. In addition, Redonda Miller, M.D., M.B.A., president of The Johns Hopkins Hospital, has stepped down from her position on the board. "We are excited to welcome Christine to our board of directors where her business acumen and deep knowledge of the biopharmaceutical industry will round out and enhance our current b
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to execute effi